Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2705

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI 10773
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: BI 10773
DRUG: Placebo
DRUG: Placebo
DRUG: BI 10773
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: BI 10773
DRUG: BI 10773
DRUG: BI 10773
DRUG: Placebo
DRUG: BI 10773
DRUG: Placebo
DRUG: Placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]